15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering TG Therapeutics Inc, 3 rate it Buy or better, 1 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $20.00 to $86.00 (about 4.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $59.00 sits 6% above the current $55.75. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.45 next quarter toward $2.96 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy360%
Hold120%
Sell120%
Strong Sell00%
Based on 5 analysts giving stock ratings to TG Therapeutics Inc.
As of Sep, 3 of 5 firms rate TGTX a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
TGTX EPS & revenue forecast
EPS · NEXT QUARTER
$0.45
Range $0.33 – $0.56 · 4 analysts · +218% YoY
Next period, 4 analysts expect TG Therapeutics Inc to earn $0.45 a share (range $0.33 – $0.56), versus $0.14 a year earlier. Full-year consensus is $0.95, growing to $2.96 the year after.
REVENUE · NEXT QUARTER
$267.9M
Range $259.6M – $282.0M · 4 analysts · +39% YoY
Revenue is expected to reach $267.9M (range $259.6M – $282.0M), +39.1% year-over-year. Full-year consensus is $960.2M, rising to $1.3B next year.
Top analysts covering TG Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TGTX.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$55.00-1.3% to target
Overall win rate
50%
+ Follow
#2
Roger Song
Jefferies · Rank #101
Buy
$83.00+48.9% to target
Overall win rate
43%
+ Follow
#3
EW
Edward White
HC Wainwright & Co. · Rank #290
Buy
$55.00-1.3% to target
Overall win rate
31%
+ Follow
#4
Emily Bodnar
HC Wainwright & Co. · Rank #399
Buy
$78.00+39.9% to target
Overall win rate
23%
+ Follow
#5
Brian Cheng
JP Morgan
Buy
$72.00+29.1% to target
Coverage
—
+ Follow
TGTX stock forecast FAQ
What is TGTX's average 12-month price target?+
The 5 analysts with a live target average $59.00 for TG Therapeutics Inc over the next 12 months, ranging from a $86.00 high to a $20.00 low.
Is TGTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 3 are Buy or Strong Buy, 1 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for TGTX?+
The Street-high target is $86.00 (B. Riley Securities), and the Street-low is $20.00 (B of A Securities). The average of all 5 active targets is $59.00.
How many Wall Street analysts cover TGTX?+
5 analysts have an active rating on TG Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering TGTX?+
Among analysts who currently cover TGTX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $55.00 target.
What is TG Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.45 per share (range $0.33 – $0.56) across 4 analysts. Full-year EPS is projected at $0.95, rising to $2.96 the following year.
How much revenue is TG Therapeutics Inc expected to report next quarter?+
Consensus revenue is $267.9M (range $259.6M – $282.0M). Full-year revenue is projected at $960.2M, growing to $1.3B next year.
Have analysts been upgrading or downgrading TGTX lately?+
As of Sep, 3 of 5 firms rate TGTX a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TGTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
